Hansoh Pharmaceutical Group (HKG:3692) said its self-developed HS-20197 injection has received clinical trial approval from China's National Medical Products Administration.
The Class 1 innovative drug is being developed for advanced solid tumors, according to a Wednesday Hong Kong exchange filing.